drugset / Trial / NCT02729376

Single-Dose Study to Assess the Absorption, Metabolism, Excretion, and Mass Balance of Radiolabeled Galeterone

NCT02729376

Phase 1 Completed 6 enrolled LTN PHARMACEUTICALS, INC.
NaSingle-groupOpen-labelBasic science

Summary

This is an open label, single dose, 1 period study of \[14C\] galeterone.

Timeline

Start
2016-03
Primary completion
2016-04
Completion
2016-04

Drugs

EvaluationDrugModalityDoseRoute
Subject galeterone Small molecule 2600 mg Oral

Indications

No indication recorded.